National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.
Oregon Health & Science University, Portland.
Arthritis Rheumatol. 2016 Feb;68(2):282-98. doi: 10.1002/art.39298. Epub 2015 Sep 24.
To provide evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA).
A core group led the development of the recommendations, starting with the treatment questions. A literature review group conducted systematic literature reviews of studies that addressed 57 specific treatment questions, based on searches conducted in OVID Medline (1946-2014), PubMed (1966-2014), and the Cochrane Library. We assessed the quality of evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method. A separate voting group reviewed the evidence and voted on recommendations for each question using the GRADE framework.
In patients with active AS, the strong recommendations included use of nonsteroidal antiinflammatory drugs (NSAIDs), use of tumor necrosis factor inhibitors (TNFi) when activity persists despite NSAID treatment, not to use systemic glucocorticoids, use of physical therapy, and use of hip arthroplasty for patients with advanced hip arthritis. Among the conditional recommendations was that no particular TNFi was preferred except in patients with concomitant inflammatory bowel disease or recurrent iritis, in whom TNFi monoclonal antibodies should be used. In patients with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with TNFi. Other recommendations for patients with nonradiographic axial SpA were based on indirect evidence and were the same as for patients with AS.
These recommendations provide guidance for the management of common clinical questions in AS and nonradiographic axial SpA. Additional research on optimal medication management over time, disease monitoring, and preventive care is needed to help establish best practices in these areas.
为治疗强直性脊柱炎(AS)和非放射学中轴型脊柱关节炎(SpA)患者提供循证推荐意见。
一个核心小组牵头制定推荐意见,首先提出治疗问题。文献综述小组根据在 OVID Medline(1946-2014 年)、PubMed(1966-2014 年)和 Cochrane 图书馆进行的检索,对 57 个具体治疗问题的研究进行了系统文献回顾。我们使用推荐评估、制定与评价(GRADE)方法评估证据质量。一个独立的投票小组审查证据,并使用 GRADE 框架对每个问题的推荐意见进行投票。
在活动期 AS 患者中,强烈推荐使用非甾体抗炎药(NSAIDs)、在 NSAID 治疗后仍有活动时使用肿瘤坏死因子抑制剂(TNFi)、不使用全身糖皮质激素、使用物理治疗和在髋关节关节炎进展时使用髋关节置换术。条件性推荐意见包括除同时患有炎症性肠病或复发性虹膜炎的患者外,不特别推荐使用任何特定的 TNFi,对于这些患者,应使用 TNFi 单克隆抗体。对于 NSAIDs 治疗后仍有活动的非放射学中轴型 SpA 患者,我们建议有条件地使用 TNFi。对于非放射学中轴型 SpA 患者的其他推荐意见则基于间接证据,与 AS 患者相同。
这些推荐意见为 AS 和非放射学中轴型 SpA 的常见临床问题的管理提供了指导。需要进一步研究随时间推移的最佳药物管理、疾病监测和预防保健,以帮助确定这些领域的最佳实践。